Connection

Evangelos Terpos to Recurrence

Back to Details
This is a "connection" page, showing publications Evangelos Terpos has written about Recurrence.
Evangelos Terpos
Connection Strength
0.350
Recurrence
  1. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. Eur J Haematol. 2018 Oct; 101(4):556-565.
    View in: PubMed
    Score: 0.090
  2. Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. Ann Hematol. 2018 Sep; 97(9):1671-1682.
    View in: PubMed
    Score: 0.088
  3. Retreatment and prolonged therapy with subcutaneous bortezomib in patients with relapsed multiple myeloma: A randomized, controlled, phase III study. Eur J Haematol. 2018 Jan; 100(1):10-19.
    View in: PubMed
    Score: 0.085
  4. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. J Cell Mol Med. 2019 12; 23(12):8010-8018.
    View in: PubMed
    Score: 0.024
  5. A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia. 2019 11; 33(11):2654-2661.
    View in: PubMed
    Score: 0.024
  6. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. Leuk Lymphoma. 2018 04; 59(4):983-987.
    View in: PubMed
    Score: 0.021
  7. Efficacy and safety of elotuzumab for the treatment of multiple myeloma. Expert Opin Drug Saf. 2017 Feb; 16(2):237-245.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.